Urinary XXXX coli antimicrobial susceptibility profiles and their relationship with community antibiotic use in Tasmania, Australia.

@entity801 @entity4258 @entity115 @entity2177 @entity798 @entity206 @entity1729 @entity7265 @entity526 @entity1536
This study assessed urinary @entity526 coli antibiotic susceptibility patterns in Tasmania, Australia, and examined their association with community antibiotic use. The susceptibility profiles of all urinary @entity526 isolates collected in Tasmania between January 2010 and December 2012 were included. The amount of Pharmaceutical Benefits Scheme (PBS)-subsidised use of @entity115 , @entity115 / @entity798 (AMC), @entity7265 , @entity4258 , @entity2177 and @entity206 was retrieved (at the Tasmanian population level) and the number of defined daily doses per 1000 population per day in Tasmania for these antibiotics was calculated for each month during the study period. Antimicrobial susceptibility data were assessed for changes over time in the 3-year study period. Antimicrobial use and susceptibility data were assessed for seasonal differences and lag in resistance following antibiotic use. Excluding duplicates, 28145 @entity526 isolates were included. Resistance levels were low; 35% of isolates were non-susceptible to @entity115 , 14% were non-susceptible to @entity206 and <5% were non-susceptible to AMC, @entity7265 , @entity801 and @entity4258 . @entity115 use increased by 35% during winter/spring compared with summer/autumn, and AMC use increased by 21%. No seasonal variation in @entity1536 use or resistance was detected. The low levels of antimicrobial resistance identified may relate to Tasmania's isolated geographical location. Significant seasonal variation in @entity115 and AMC use is likely to be due to increased use of these antibiotics for treatment of @entity1729 in winter. @entity1536 use is restricted by the PBS in Australia, which is the likely explanation for the low levels of @entity1536 use and resistance identified.
